PL4157832T3 - Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania - Google Patents
Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowaniaInfo
- Publication number
- PL4157832T3 PL4157832T3 PL21733318.6T PL21733318T PL4157832T3 PL 4157832 T3 PL4157832 T3 PL 4157832T3 PL 21733318 T PL21733318 T PL 21733318T PL 4157832 T3 PL4157832 T3 PL 4157832T3
- Authority
- PL
- Poland
- Prior art keywords
- glp
- agonists
- salt
- crystal forms
- crystal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/22—Tricarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020092530 | 2020-05-27 | ||
| PCT/US2021/034191 WO2021242817A1 (en) | 2020-05-27 | 2021-05-26 | Salt and crystal forms of glp-1r agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4157832T3 true PL4157832T3 (pl) | 2024-12-16 |
Family
ID=76502864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21733318.6T PL4157832T3 (pl) | 2020-05-27 | 2021-05-26 | Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230203023A1 (pl) |
| EP (1) | EP4157832B1 (pl) |
| JP (1) | JP7702973B2 (pl) |
| CN (1) | CN115867546B (pl) |
| AU (1) | AU2021281237A1 (pl) |
| CA (1) | CA3179890A1 (pl) |
| DK (1) | DK4157832T3 (pl) |
| ES (1) | ES2985435T3 (pl) |
| FI (1) | FI4157832T3 (pl) |
| HU (1) | HUE068535T2 (pl) |
| PL (1) | PL4157832T3 (pl) |
| PT (1) | PT4157832T (pl) |
| TW (1) | TWI913272B (pl) |
| WO (1) | WO2021242817A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| PE20221040A1 (es) | 2019-10-25 | 2022-06-17 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| CA3168543A1 (en) | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| CN113773310B (zh) * | 2020-06-10 | 2023-12-22 | 重庆康丁医药技术有限公司 | 一种具有心血管益处的glp-1小分子 |
| WO2022109182A1 (en) | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| JP7772778B2 (ja) | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| PL4271672T3 (pl) | 2021-04-21 | 2026-04-20 | Gilead Sciences, Inc. | Karboksybenzimidazolowe związki modulujące glp-1r |
| WO2023029380A1 (zh) | 2021-08-30 | 2023-03-09 | 杭州德睿智药科技有限公司 | 作为glp1r激动剂的新型芳醚取代杂环类化合物 |
| AU2022344074A1 (en) | 2021-09-08 | 2024-02-29 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| FI4408840T3 (fi) | 2021-09-27 | 2025-11-04 | Terns Pharmaceuticals Inc | Bentsimidatsolikarboksyylihappoja glp-1r-agonisteina |
| IL312364A (en) | 2021-10-25 | 2024-06-01 | Luehr Gary W | Compounds as GLP-1R agonists |
| JP2024547112A (ja) * | 2021-12-23 | 2024-12-26 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｇｌｐ－１受容体作動薬の結晶形及びその調製方法 |
| US12410163B2 (en) | 2022-02-23 | 2025-09-09 | Terns Pharmaceuticals, Inc. | Compounds as GLP-IR agonists |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| KR20250029972A (ko) * | 2022-07-18 | 2025-03-05 | 민드랭크 테라퓨틱스 (수저우) 뉴 드러그 리서치 앤 디벨롭먼트 컴퍼니, 리미티드 | Glp-1r 작용제의 결정다형체 및 이의 제조 방법과 용도 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| WO2024211898A1 (en) | 2023-04-07 | 2024-10-10 | Terns Pharmaceuticals, Inc. | Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2026092581A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
| WO2026092580A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| BR112015031040A8 (pt) | 2013-06-11 | 2018-01-02 | Receptos Inc | Novos moduladores do receptor de glp-1 |
| TW201613883A (en) | 2014-10-14 | 2016-04-16 | Nat Res Inst Of Chinese Medicine Ministry Of Health And Welfare | Compounds capable of regulating activity of GLP-1 receptor and its application |
| CN110325530B (zh) * | 2016-12-16 | 2022-01-11 | 辉瑞大药厂 | Glp-1受体激动剂及其用途 |
| CU20210042A7 (es) * | 2018-11-22 | 2022-01-13 | Qilu Regor Therapeutics Inc | Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen |
| TW202144340A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN111978313B (zh) * | 2020-08-28 | 2022-01-18 | 深圳大学 | 具备聚集诱导发光性质的多模态光诊疗剂及其制备与应用 |
-
2021
- 2021-05-26 PL PL21733318.6T patent/PL4157832T3/pl unknown
- 2021-05-26 HU HUE21733318A patent/HUE068535T2/hu unknown
- 2021-05-26 DK DK21733318.6T patent/DK4157832T3/da active
- 2021-05-26 EP EP21733318.6A patent/EP4157832B1/en active Active
- 2021-05-26 JP JP2022572686A patent/JP7702973B2/ja active Active
- 2021-05-26 TW TW110119087A patent/TWI913272B/zh active
- 2021-05-26 ES ES21733318T patent/ES2985435T3/es active Active
- 2021-05-26 FI FIEP21733318.6T patent/FI4157832T3/fi active
- 2021-05-26 PT PT217333186T patent/PT4157832T/pt unknown
- 2021-05-26 WO PCT/US2021/034191 patent/WO2021242817A1/en not_active Ceased
- 2021-05-26 CN CN202180041199.0A patent/CN115867546B/zh active Active
- 2021-05-26 CA CA3179890A patent/CA3179890A1/en active Pending
- 2021-05-26 AU AU2021281237A patent/AU2021281237A1/en active Pending
- 2021-05-26 US US17/927,502 patent/US20230203023A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2985435T3 (es) | 2024-11-05 |
| US20230203023A1 (en) | 2023-06-29 |
| PT4157832T (pt) | 2024-07-30 |
| CA3179890A1 (en) | 2021-12-02 |
| WO2021242817A1 (en) | 2021-12-02 |
| JP2023527997A (ja) | 2023-07-03 |
| TWI913272B (zh) | 2026-02-01 |
| TW202210473A (zh) | 2022-03-16 |
| EP4157832B1 (en) | 2024-06-19 |
| EP4157832A1 (en) | 2023-04-05 |
| CN115867546B (zh) | 2024-10-18 |
| JP7702973B2 (ja) | 2025-07-04 |
| AU2021281237A1 (en) | 2023-01-19 |
| HUE068535T2 (hu) | 2025-01-28 |
| DK4157832T3 (da) | 2024-09-23 |
| CN115867546A (zh) | 2023-03-28 |
| FI4157832T3 (fi) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE068535T2 (hu) | GLP-1R agonisták sója és kristályformái és azok felhasználásai | |
| IL287472A (en) | Crystalline form of wee1 inhibitory compound and use thereof | |
| EP4228753C0 (en) | CRYSTALLINE FORMS OF GLP-1 R AGONISTS AND THEIR USES | |
| ZA202007037B (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
| EP3825309A4 (en) | LSD1 INHIBITOR SALT AND POLYMORPH THEREOF | |
| SG11202105241YA (en) | Glp-1r agonists and uses thereof | |
| SG11202109438TA (en) | A salt and crystal form of a fak inhibitor | |
| IL279717A (en) | Amino acid compounds with non-branched linkers and methods of use | |
| IL277326A (en) | Polymorphs of calcium salts that suppress dihydroureoate dehydrogenase, and methods for their production | |
| SG11202001153RA (en) | Leucoindigo salt solution with very low content of aniline and method of making same | |
| GB202003778D0 (en) | Use of lactoferrin | |
| IL319797B1 (en) | Method for synthesizing a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of a salt thereof | |
| ZA202003581B (en) | Crystal form of urat1 inhibitor, and preparation method therefor | |
| EP4249476A4 (en) | Salt of a benzothiazole compound, crystal form and use thereof | |
| IL309469A (en) | Salt and crystal forms of epidermal growth factor receptor inhibitor | |
| PT3725786T (pt) | Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas | |
| IL308804A (en) | TREM2 agonistic biomarkers and methods of using them | |
| ZA202101589B (en) | Crystal form of tri-cycle compound and application thereof | |
| EP3650444B8 (en) | Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof | |
| ZA202007347B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| EP3901149A4 (en) | IMPURITIES OF AMIDE DERIVATIVES AND THEIR USE | |
| EP4438606A4 (en) | NEW CRYSTALLINE FORM OF A NUCLEOSIDE COMPOUND AND ITS SALT | |
| GB2571229B (en) | Additives to reduce the crystallization temperature of brines and methods of use | |
| PT3441431T (pt) | Métodos de fabrico de soluções de sal leucoindigo com teor de anilina muito baixo | |
| EP4130004A4 (en) | SALT AND CRYSTALLINE FORMS OF FGFR4 INHIBITOR AND THEIR USES |